CEACAM5 and neoplasm: Additionally, the investigation into other inflammation scores (like PLR, NLR, and SII) and conventional serological tumor biomarkers (including CEA, CA72‐4, CA125, CA19‐9, and AFP) revealed limited effectiveness in distinguishing responders from non‐responders to combination immunotherapy.